A Study of LY3478006 in Healthy Participants

Phase 1

Terminated

Interventions: Drug: LY3478006 - IV
Drug: Placebo - IV
Drug: LY3478006 - SC
Drug: Placebo - SC

Brief Summary: The purpose of this study is to learn more about how safe and how well tolerated LY3478006 is when given by injection into a vein or just under the skin to healthy participants. Blood tests will be done to check how much LY3478006 is in the bloodstream and how long the body takes to get rid of it. For each participant, the study will last up to about 16 weeks, including screening.

Recruitment & Eligibility

Inclusion Criteria

Are overtly healthy male or female Japanese or non-Japanese participants, as determined by medical history and physical examination
Women not of childbearing potential
Are aged 18 to 55 years (20 to 55 years for Japanese participants), inclusive, at screening

Exclusion Criteria

Have clinically significant abnormal electrocardiogram (ECG) results
Have persistent abnormal blood pressure or pulse rate, as determined by the investigator
Have evidence of orthostatic hypotension, defined as a decrease in systolic or diastolic blood pressure greater than or equal to (≥)20 millimeters of mercury (mmHg) or ≥10 mmHg, respectively
Have significant history or presence of cardiovascular, respiratory, hepatic, ophthalmological, renal, gastrointestinal, endocrine, hematological, neurological, or psychiatric disorders
Have a history or presence of mononeuropathy, polyneuropathy, or autonomic neuropathy
Have significant allergies to humanized monoclonal antibodies

Arm && Interventions

Group	Intervention	Description
10 milligram (mg) LY3478006 - Intravenous (IV)	LY3478006 - IV	Participants received single dose of 10 mg LY3478006 administered IV. Due to early termination of the study Cohort 2 to 6 (30 mg, 100 mg, 300 mg, 600 mg, and 1000 mg LY3478006 IV) were not explored for safety reasons following dosing of the first 4 participants in Cohort 1.
Placebo - IV	Placebo - IV	Participants received single dose of placebo administered IV. Placebo IV Cohorts 2 through 6 were not explored as study was terminated for safety reasons following dosing of the first 4 participants in cohort 1.
100 mg LY3478006 - Subcutaneous (SC) (Cohort 7)	LY3478006 - SC	100 mg LY3478006 cohort 7 SC dose was not explored as study was terminated for safety reasons following dosing of the first 4 participants in cohort 1.
Placebo - SC (Cohort 7)	Placebo - SC	Placebo cohort 7 SC dose were not explored as study was terminated for safety reasons following dosing of the first 4 participants in cohort 1.

Primary Outcome Measures

Name	Time	Method
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Baseline through study completion (up to 109 days)	Data presented are the number of participants who experienced SAEs considered by the investigator to be related to study drug administration. A summary of SAEs and all other non-serious Adverse Event(s) (AEs), regardless of causality, is located in the Reported Adverse Event module.

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3478006	Predose; Day 1 with end of infusion, 3, 6, 12 hours	Cmax of LY3478006 was evaluated.
PK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC0-∞) of LY3478006	Predose; Day 1 with end of infusion, 3, 6, 12 hours; Day 2; Day 3; Day 5; Day 8; Day 10; Day 15; Day 22; Day 29; Day 43; Day 57; Day 71 and Day 85	AUC0-∞ of LY3478006 was evaluated. The unit of measure is hour\microgram per milliliter (hr\mcg/mL).

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial